What Fueled The Previous Growth In The Genomics Personalized Health Market?
The genomics personalized health market has seen considerable growth due to a variety of factors.
• The genomics personalized health market has experienced rapid growth in recent years. It is anticipated to increase from $15.97 billion in 2024 to $18.58 billion in 2025, with a compound annual growth rate (CAGR) of 16.4%.
Historical growth is attributed to breakthroughs in genomics research, government funding and support, the rise in chronic diseases, technological innovations, and investments and partnerships within the pharmaceutical industry.
How Does the Forecast Look for the Genomics Personalized Health Market?
The genomics personalized health market is expected to maintain its strong growth trajectory in upcoming years.
• The genomics personalized health market is projected to grow rapidly, reaching $33.6 billion by 2029, at a CAGR of 16.0%.
This growth can be attributed to higher healthcare investments, broader adoption of genomics technologies, expanded applications of personalized medicine, the rising prevalence of genetic disorders, the growth of biobanks, and the increasing prevalence of chronic diseases. Key trends will include the integration with wearable technology, growth in direct-to-consumer genetic testing, advancements in CRISPR and gene editing, the fusion of genomics with digital health, and the expansion of precision medicine initiatives.
What Are The Leading Drivers Of Growth In The Genomics Personalized Health Market?
The genomics personalized health market is expected to grow due to the increasing demand for personalized medicine. This healthcare model tailors treatments based on individual genetic profiles, improving treatment outcomes, patient engagement, and addressing complex diseases. The genomics personalized health market is essential for advancing personalized medicine by leveraging genetic information for targeted care. For example, in 2023, the FDA approved 16 new personalized therapies, up from six in 2022, according to the Personalized Medicine Coalition. Thus, the rising demand for personalized medicine is driving the genomics personalized health market.
How Are The Segments Defined Within The Global Genomics Personalized Health Market?
The genomics personalized health market covered in this report is segmented –
1) By Test Type: Oncology Testing, Infectious Disease Testing, Orphan Disease Testing, Autoimmune Disease Testing, Obstetrics Testing, Other Test Type
2) By Technology: NGS platforms, RT-PCR, Microarray, Genetic Analyzers
3) By End User: Academic Research Institutes, Diagnostic Centers, Other End Users
Subsegments:
1) Oncology Testing: Cancer Genomic Profiling, Liquid Biopsy Testing, Tumor Mutational Burden Testing, Genetic Biomarker Testing
2) Infectious Disease Testing: PCR-Based Tests, Next-Generation Sequencing (NGS) Tests, Microbial Genomic Profiling
3) Orphan Disease Testing: Genetic Screening For Rare Diseases, Genetic Testing For Inherited Disorders, Targeted Gene Panels
4) Autoimmune Disease Testing: Genetic Screening For Autoimmune Conditions, Immune System Gene Profiling, HLA Typing Tests
5) Obstetrics Testing: Non-Invasive Prenatal Testing (NIPT), Genetic Screening For Birth Defects, Carrier Screening Tests
6) Other Test Type: Cardiovascular Genetic Testing, Neurological Disease Testing, Metabolic Disease Genetic Testing
Pre-Book The Genomics Personalized Health Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Genomics Personalized Health Market?
Leading companies in the genomics personalized health market are concentrating on creating innovative products such as cloud-based software for the tertiary analysis of clinical next-generation sequencing (NGS) data to enhance their market dominance. The term clinical next-generation sequencing (NGS) data refers to the genome data produced by high-capacity sequencing technologies that enable comprehensive DNA or RNA sample analysis in a clinical context. For example, Illumina, a U.S. biotech firm that specializes in DNA sequencing and array-based technologies, launched Connected Insights in March 2023. This cloud-based software is designed for the tertiary analysis of clinical next-generation sequencing (NGS) data, and its primary goal is to simplify the interpretation and reporting procedures, especially in the field of oncology. It supports full genomic profiling, and it integrates various third-party knowledge databases, which helps enhance the accuracy of data analysis and improves the efficiency of precision care initiatives.
Who Are the Key Players In The Genomics Personalized Health Market?
Major companies operating in the genomics personalized health market are:
• F. Hoffmann-La Roche AG
• Thermo Fisher Scientific Inc.
• Quest Diagnostics
• Agilent Technologies Inc.
• Lonza Group
• PerkinElmer Inc.
• Illumina Inc.
• Bio-Rad Laboratories Inc.
• Exact Sciences Corporation
• QIAGEN N.V
• Natera Inc.
• Adaptive Biotechnologies Corporation
• Myriad Genetics Inc.
• NanoString Technologies Inc.
• Pacific Biosciences of California Inc.
• Personalis Inc.
• DNA Genotek Inc.
• Twist Bioscience Corporation
• GRAIL Inc.
• Eastern Biotech and Life Sciences
• INVITAE Corporation
• Genetic Technologies Limited
• XCode Life Sciences Private Limited
• Biome Inc.
• BGI Genomics Co. Ltd.
What Is The Most Dominant Region In The Genomics Personalized Health Market?
North America was the largest region in the personalized health market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomics personalized health market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
